Cure Today1 天
FDA Grants Breakthrough Therapy Designation to Trodelvy for Small Cell Lung Cancer
The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...
腾讯网5 天
Trop-2靶向ADC再获突破性疗法认定，治疗难治性肺癌
01 吉利德科学公司宣布，美国FDA已授予Trodelvy突破性疗法认定，用于治疗接受铂类化疗后疾病进展的广泛期小细胞肺癌 (ES-SCLC)成人患者。 04 目前，Trodelvy已在超过50个国家和地区获批，用于治疗经治转移性三阴性乳腺癌 ...
The Pharma Letter7 天
FDA Breakthrough status for Trodelvy in ES-SCLC
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Trodelvy (sacituzumab ...
腾讯网7 天
翰森制药「HS-20093」获欧EMA优先药物认定
12月17日，翰森制药企业官微发布消息称，其合作方葛兰素史克（GSK）就GSK5764227 (GSK'227,亦称HS-20093)获得欧洲药品管理局 (EMA) 优先药物（PRIME）认定。
Targeted Oncology7 天
FDA Grants Breakthrough Status to Sacituzumab Govitecan in ES-SCLC
The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum ...
Zacks.com on MSN6 天
GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer
Gilead Sciences GILD announced that its first-in-class Trop-2-directed antibody-drug conjugate, Trodelvy (sacituzumab ...
腾讯网7 天
翰森制药(03692.HK)HS-20093获欧洲药品管理局优先药物认定
【财华社讯】翰森制药(03692.HK)公布，GSK就GSK5764227(GSK’227，亦称 ...
Genprex肺癌试验进入二期阶段
安全审查委员会 (SRC)已确定REQORSA的推荐二期剂量 (RP2D)为0.12 mg/kg，这是一期试验中测试的最高剂量水平。二期扩展将在10至15个美国站点评估约50名患者的18周无进展生存率。尽管该股票显示出显著的波动性，beta值为-1.38，但分析师保持看涨观点，目标价为7.50美元。
Daily5 天
Gilead Sciences earns USFDA Breakthrough Therapy Designation for lung cancer treatment Trodelvy
Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy Designation ...
来自MSN17 天
复宏汉霖PD-1抗体药物获批非鳞状非小细胞肺癌新适应症
这是该产品在中国获批的第五项适应症，也是继鳞状非小细胞肺癌（sqNSCLC)、广泛期小细胞肺癌（ES-SCLC)后，该产品在肺癌领域获批的第三项适应症。
FDA Grants Breakthrough Therapy Status To Gilead's Trodelvy For Treatment Of Small Cell ...
(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adults with ...